Osocimab

DB14818InvestigationalProtein Based Therapies

Osocimab is under investigation in clinical trial NCT03276143 (Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty).

Mechanism: Pharmacologically active on Coagulation factor XI
Curator reviewed
Code names: BAY-1213790

Resolves to

Compound

UNIIEK5V9UL3WLCAS2056878-75-0

Targets

P03951F11

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Osocimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account